BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 22505700)

  • 1. Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.
    Yu X; Wang L; Xu P; Lu W; Lan G; Ping L; Wang X; Tian J; Liu J
    J Rheumatol; 2012 Jun; 39(6):1171-8. PubMed ID: 22505700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.
    Yu X; Zhang L; Wang L; Lu W; Sun F; Xu P; Lan G
    Clin Rheumatol; 2018 Apr; 37(4):917-925. PubMed ID: 29313271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.
    Yu X; Ma J; Tian J; Jiang S; Xu P; Han H; Wang L
    J Clin Rheumatol; 2007 Aug; 13(4):193-8. PubMed ID: 17762452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
    O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
    Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging.
    Kosta PE; Voulgari PV; Zikou AK; Tsampoulas K; Drosos AA; Argyropoulou MI
    Scand J Rheumatol; 2012 Oct; 41(5):339-44. PubMed ID: 22646866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Hakala M; Järvinen P; Ahonen J; Forsberg S; Leirisalo-Repo M;
    Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
    Pincus T; Amara I; Koch GG
    Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
    J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V; Tugwell P; Bombardier C; Maetzel A; Crawford B; Dorrier C; Thompson A; Wells G
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
    Tam LS; Shang Q; Li EK; Wang S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
    J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS; Park YW; Park JJ; Kang YM; Nam EJ; Kim SI; Lee JH; Yoo WH; Lee SI
    Scand J Rheumatol; 2009; 38(1):11-4. PubMed ID: 19191187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.